Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in metastatic oesophageal squamous cell carcinoma
2017-004730-28Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: 9-month overall survival rate. Started Jul 2018; status: completed.
02
Drugs
irinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2017-004730-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004730-28.